Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 16 studies | 34% ± 12% | |
lung | 12 studies | 29% ± 13% | |
intestine | 7 studies | 20% ± 7% | |
kidney | 7 studies | 21% ± 5% | |
brain | 5 studies | 23% ± 4% | |
bone marrow | 4 studies | 28% ± 7% | |
uterus | 4 studies | 29% ± 13% | |
lymph node | 4 studies | 28% ± 5% | |
liver | 4 studies | 28% ± 11% | |
breast | 3 studies | 20% ± 1% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 100% | 5879.88 | 459 / 459 | 100% | 96.46 | 1118 / 1118 |
esophagus | 100% | 6257.47 | 1445 / 1445 | 100% | 125.25 | 183 / 183 |
lung | 100% | 6806.24 | 578 / 578 | 100% | 102.14 | 1155 / 1155 |
uterus | 100% | 6803.15 | 170 / 170 | 100% | 91.99 | 458 / 459 |
stomach | 100% | 4109.63 | 359 / 359 | 100% | 91.55 | 285 / 286 |
bladder | 100% | 6438.57 | 21 / 21 | 100% | 89.06 | 502 / 504 |
prostate | 100% | 5327.03 | 245 / 245 | 100% | 52.52 | 500 / 502 |
thymus | 100% | 5195.06 | 653 / 653 | 99% | 71.95 | 601 / 605 |
kidney | 100% | 5651.11 | 89 / 89 | 99% | 72.50 | 895 / 901 |
ovary | 100% | 5687.06 | 180 / 180 | 99% | 112.11 | 426 / 430 |
intestine | 100% | 6775.56 | 966 / 966 | 99% | 82.41 | 521 / 527 |
brain | 97% | 2122.50 | 2572 / 2642 | 100% | 49.30 | 702 / 705 |
skin | 100% | 6899.08 | 1809 / 1809 | 95% | 64.69 | 450 / 472 |
pancreas | 95% | 1859.19 | 312 / 328 | 98% | 69.29 | 175 / 178 |
adrenal gland | 100% | 4639.01 | 258 / 258 | 91% | 28.01 | 209 / 230 |
liver | 99% | 2049.61 | 224 / 226 | 89% | 29.65 | 361 / 406 |
adipose | 100% | 6617.43 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 6047.52 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 176.73 | 29 / 29 |
spleen | 100% | 8946.14 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 98.42 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 34.45 | 1 / 1 |
peripheral blood | 99% | 11953.25 | 924 / 929 | 0% | 0 | 0 / 0 |
heart | 98% | 2923.52 | 845 / 861 | 0% | 0 | 0 / 0 |
muscle | 95% | 1873.70 | 766 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 71% | 23.11 | 57 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0001934 | Biological process | positive regulation of protein phosphorylation |
GO_0035329 | Biological process | hippo signaling |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0043539 | Molecular function | protein serine/threonine kinase activator activity |
GO_0030295 | Molecular function | protein kinase activator activity |
GO_0005515 | Molecular function | protein binding |
GO_0046872 | Molecular function | metal ion binding |
Gene name | MOB1A |
Protein name | MOB kinase activator 1A (Mob1 alpha) (Mob1A) (Mob1 homolog 1B) (Mps one binder kinase activator-like 1B) |
Synonyms | MOB4B MOBKL1B C2orf6 MOBK1B |
Description | FUNCTION: Activator of LATS1/2 in the Hippo signaling pathway which plays a pivotal role in organ size control and tumor suppression by restricting proliferation and promoting apoptosis. The core of this pathway is composed of a kinase cascade wherein STK3/MST2 and STK4/MST1, in complex with its regulatory protein SAV1, phosphorylates and activates LATS1/2 in complex with its regulatory protein MOB1, which in turn phosphorylates and inactivates YAP1 oncoprotein and WWTR1/TAZ. Phosphorylation of YAP1 by LATS1/2 inhibits its translocation into the nucleus to regulate cellular genes important for cell proliferation, cell death, and cell migration. Stimulates the kinase activity of STK38 and STK38L. Acts cooperatively with STK3/MST2 to activate STK38. . |
Accessions | ENST00000396049.5 [Q9H8S9-1] Q9H8S9 |